Frédéric de Blay, EAACI 2021: Anti-Fel D 1 Monoclonal Antibodies Reduce the Rate of Early Asthma Responses
touchRESPIRATORY joins Professor Frédéric de Blay (University Hospital of Strasbourg, Strasbourg, France) at EAACI 2021 to discuss the results of a phase 2, randomised, double-blind, placebo-controlled study of anti-Fel d 1 monoclonal antibodies in reducing the rate of early asthma responses, chest symptoms and rescue medication use in cat-allergic subjects with mild asthma for up to 3 months following a controlled cat allergen challenge.
1. Could you give us a brief overview of the health burden of cat allergy? (00:29-01:57)
2. What are anti-Fel d 1 monoclonal antibodies and what is the rationale for use in combating cat allergy? (01:57 -02:43)
3. What were the aims and design of the Phase 2 study? (02:43-04:00)
4. What were the efficacy and safety findings of the study? (04:00-05:00)
5. What will be the next step in the clinical development of anti-Fel d 1 monoclonal antibodies? (05:00-06:04)
Disclosures: Professor Frédéric de Blay has no financial or non-financial conflicts of interest to declare in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.
Filmed in coverage of the 2021 EAACI Annual Meeting.
Share this Video
Related Videos In Allergy
Isaac Schmale, AAAAI 2023: Efficacy of dupilumab for nasal polyposis in patients with aspirin-exacerbated respiratory disease
Dupilumab is used to manage chronic rhinosinusitis with nasal polyposis, however there is limited data regarding its use in patients with aspirin-exacerbated respiratory disease (AERD). touchRESPIRATORY caught up with Dr Isaac Schmale (University of Rochester Medical Center, Rochester, NY, USA) around the aims, eligibility, methodology and findings of his study investigating the real-world outcomes of […]
Isaac Schmale, AAAAI 2023: Signs and symptoms of aspirin-exacerbated respiratory disease and its treatment paradigm
touchRESPIRATORY were delighted to speak with Dr Isaac Schmale (University of Rochester Medical Center, Rochester, NY, USA) around the signs and symptoms of aspirin-exacerbated respiratory disease (AERD), the incidence of AERD in people with asthma, the current treatment paradigm for AERD and the unmet needs in its treatment. The abstract ‘Real-world Outcomes of Dupilumab Therapy […]
Ozge Can Bostan, EAACI 2022: Low Dose Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis
Mepolizumab is currently approved for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) at a dose of 300mg. touchRESPIRATORY caught up with Dr. Ozge Can Bostan (Hacettepe University School of Medicine, Ankara, Turkey) to discuss the 1 year findings from her study investigating the sinonasal and respiratory outcomes of a low dose of mepolizumab (100 […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!